Synergy Pharmaceuticals Inc. is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal (GI) therapies. The company has market cap of $1.01 billion. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It currently has negative earnings. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.
The director of First Acceptance Corp, Rhodes Bobbitt has made an unexpected transaction in the public company that is having a worth of $4,865 U.S. Dollars. As stated in the SEC document filed on March 21, 2017, Rhodes obtained 3,639 shares which is based on an average stock price per share of $1.3. The probability of this investment remaining undiscovered is nil because it’s new, with Rhodes Bobbitt now owning 684,609 shares —- that is 1.68% of the Company’s market capitalization.
Investors sentiment decreased to 0.45 in Q4 2016. Its down 0.15, from 0.6 in 2016Q3. It turned negative, as 4 investors sold First Acceptance Corporation shares while 7 reduced holdings. 1 funds opened positions while 4 raised stakes. 8.18 million shares or 1.70% less from 8.33 million shares in 2016Q3 were reported. State Street Corporation holds 10,746 shares. Spark Invest Mgmt Lc invested in 0% or 26,800 shares. Wells Fargo Mn accumulated 180,156 shares. Royal Bankshares Of Canada owns 3,500 shares or 0% of their US portfolio. Dimensional Fund Advsr Ltd Partnership owns 2.07 million shares for 0% of their portfolio. Delaware-based Blackrock Advsr has invested 0% in First Acceptance Corporation (NYSE:FAC). National Bank & Trust Of Mellon stated it has 10,436 shares. Vanguard Grp Incorporated invested 0% in First Acceptance Corporation (NYSE:FAC). Moreover, Blackrock Fund Advisors has 0% invested in First Acceptance Corporation (NYSE:FAC). First Wilshire Mgmt reported 0.05% of its portfolio in First Acceptance Corporation (NYSE:FAC). Blackrock Institutional Tru Na stated it has 79,123 shares. California Public Employees Retirement System holds 0% or 25,900 shares in its portfolio. Walleye Trading Limited Co holds 0% of its portfolio in First Acceptance Corporation (NYSE:FAC) for 505 shares. Geode Capital Management Limited Liability Corp reported 28,734 shares stake. Nationwide Fund Advsr invested 0% in First Acceptance Corporation (NYSE:FAC).
The stock decreased 0.71% or $0.01 on March 21, reaching $1.4. About shares traded. First Acceptance Corporation (NYSE:FAC) has declined 14.11% since August 15, 2016 and is downtrending. It has underperformed by 21.14% the S&P500.
First Acceptance Corporation is a retailer, servicer and underwriter of non-standard personal automobile insurance based in Nashville, Tennessee. The company has market cap of $56.42 million. The Firm operates in two divisions: Insurance, and Real estate and corporate. It currently has negative earnings. The Company’s insurance activities are engaged in selling non-standard personal automobile insurance products and related products in over 20 states.
Analysts await First Acceptance Corporation (NYSE:FAC) to report earnings on May, 9.
Since November 14, 2016, it had 3 buys, and 0 sales for $144,387 activity. Shares for $28,698 were bought by Bobbitt Rhodes R on Thursday, December 15.
Analysts await Synergy Pharmaceuticals Inc (NASDAQ:SGYP) to report earnings on May, 9. They expect $-0.18 EPS, up 37.93% or $0.11 from last year’s $-0.29 per share. After $-0.31 actual EPS reported by Synergy Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -41.94% EPS growth.
The stock decreased 8.64% or $0.44 during the last trading session, reaching $4.65. About shares traded. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has declined 8.10% since August 15, 2016 and is downtrending. It has underperformed by 15.13% the S&P500.
Great Point Partners Llc holds 6.22% of its portfolio in Synergy Pharmaceuticals Inc for 4.97 million shares. Armistice Capital Llc owns 1.70 million shares or 2.45% of their US portfolio. Moreover, Orbimed Advisors Llc has 1.42% invested in the company for 18.24 million shares. The Massachusetts-based Cormorant Asset Management Llc has invested 1.23% in the stock. Trellus Management Company Llc, a New York-based fund reported 100,864 shares.
Ratings analysis reveals 83% of Synergy Pharmaceuticals’s analysts are positive. Out of 6 Wall Street analysts rating Synergy Pharmaceuticals, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $4 while the high is $20. The stock’s average target of $12 is 158.06% above today’s ($4.65) share price. SGYP was included in 11 notes of analysts from August 25, 2015. The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has “Buy” rating given on Thursday, October 29 by TH Capital. On Thursday, October 29 the stock rating was reinitiated by Roth Capital with “”. Rodman & Renshaw maintained it with “Buy” rating and $15 target in Monday, May 9 report. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, October 1. Rodman & Renshaw maintained it with “Buy” rating and $16 target in Monday, March 21 report. The firm has “Outperform” rating by Oppenheimer given on Thursday, January 5. The stock has “Neutral” rating by Citigroup on Wednesday, March 16. As per Friday, December 18, the company rating was downgraded by Citigroup. The firm has “Buy” rating given on Tuesday, August 25 by BTIG Research. The stock has “Buy” rating by Rodman & Renshaw on Friday, December 23.
Since January 1, 0001, it had 0 buys, and 2 selling transactions for $903,000 activity.
